Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.150
-0.020 (-1.71%)
Sep 8, 2026, 11:31 AM EDT - Market open

Metagenomi Therapeutics Revenue

Metagenomi Therapeutics had revenue of $-257.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $13.56M, down -59.84% year-over-year. In the year 2025, Metagenomi Therapeutics had annual revenue of $25.21M, down -51.79%.

Revenue (ttm)
$13.56M
Revenue Growth
-59.84%
P/S Ratio
3.26
Revenue / Employee
$120,009
Employees
113
Market Cap
43.44M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202525.21M-27.09M-51.79%
Dec 31, 202452.30M7.54M16.84%
Dec 31, 202344.76M27.56M160.21%
Dec 31, 202217.20M16.96M6,978.19%
Dec 31, 2021243.00K--

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company NameRevenue
Karyopharm Therapeutics146.62M
Celularity26.55M
Werewolf Therapeutics21.00M
Veru Inc.16.89M
Immutep13.79M
Mereo BioPharma Group500.00K
aTyr Pharma190.00K
Revenue Rankings